Skip to main content

Table 3 Dosimetric parameters of OARs and delivery efficiency for whole and partial arc plans on the Trilogy and Halcyon

From: Treatment planning comparison of volumetric modulated arc therapy with the trilogy and the Halcyon for bilateral breast cancer

  T-4arc T-8arc H-4arc H-8arc p < 0.05
Heart      
 V5 (%) 20.4 ± 6.2 13.7 ± 4.9 30.5 ± 6.2 49.2 ± 4.5 a,b,c,d
 V10 (%) 8.5 ± 3.3 8.0 ± 3.7 10.2 ± 2.9 15.0 ± 6.4 –
 V20 (%) 3.4 ± 1.5 4.0 ± 2.4 2.7 ± 1.3 5.8 ± 4.0 b
 V30 (%) 1.1 ± 0.6 1.8 ± 1.7 0.8 ± 0.5 2.7 ± 2.8 b,c
 V40 (%) 0.2 ± 0.2 0.6 ± 0.9 0.1 ± 0.1 1.1 ± 1.8 b,c
 Dmean (Gy) 4.9 ± 0.6 3.9 ± 1.1 5.6 ± 0.6 7.1 ± 1.6 a,b,c,d
LV      
 V5 (%) 34.2 ± 10.3 23.9 ± 7.6 35.7 ± 9.3 48.9 ± 14.8 a,c
 V10 (%) 17.5 ± 6.6 15.5 ± 6.6 16.1 ± 5.9 22.9 ± 9.8 –
 V20 (%) 7.6 ± 3.0 9.1 ± 5.2 5.8 ± 2.7 12.0 ± 7.7 b
 V30 (%) 2.7 ± 1.3 4.7 ± 4.0 1.9 ± 1.0 6.5 ± 6.2 b,c
 V40 (%) 0.5 ± 0.5 1.6 ± 2.0 0.2 ± 0.1 2.9 ± 4.1 a,b,c
 Dmean (Gy) 6.9 ± 1.3 6.0 ± 2.0 6.8 ± 1.1 9.2 ± 3.0 b
 LAD      
 V5 (%) 85.7 ± 14.5 76.0 ± 11.4 84.6 ± 13.4 89.3 ± 8.7 –
 V10 (%) 61.6 ± 16.5 63.6 ± 16.9 63.2 ± 17.2 67.5 ± 16.6 –
 V20 (%) 43.3 ± 17.7 47.5 ± 21.8 43.1 ± 19.1 52.9 ± 21.7 –
 V30 (%) 24.2 ± 15.5 25.7 ± 20.5 14.3 ± 10.9 31.2 ± 18.2 b
 V40 (%) 1.2 ± 1.5 6.5 ± 15.4 0.1 ± 0.3 9.8 ± 15.9 b
 Dmax (Gy) 40.4 ± 4.2 41.9 ± 4.2 38.9 ± 3.1 42.5 ± 4.4 b
 Dmean (Gy) 18.1 ± 4.7 19.0 ± 6.3 17.2 ± 4.0 21.3 ± 5.8 b
Lungs      
 V5 (%) 45.1 ± 3.1 30.4 ± 3.5 43.7 ± 4.1 49.1 ± 4.7 a,b,c
 V10 (%) 23.9 ± 2.6 19.4 ± 2.6 22.9 ± 2.6 25.5 ± 2.9 a,c
 V20 (%) 13.4 ± 2.2 12.4 ± 2.6 13.2 ± 2.5 15.8 ± 3.0 –
 V30 (%) 7.9 ± 1.8 8.5 ± 2.3 8.0 ± 2.1 10.6 ± 3.0 –
 V40 (%) 3.2 ± 1.1 5.0 ± 1.9 3.5 ± 1.4 6.0 ± 2.5 a,b
 Dmean (Gy) 9.1 ± 0.7 7.5 ± 1.0 9.1 ± 0.8 9.2 ± 3.0 a,c
Skin      
 V30 (%) 67.3 ± 8.7 68.9 ± 8.2 74.2 ± 7.6 75.2 ± 6.9 c,d
 V40 (%) 31.3 ± 7.9 32.4 ± 8.5 40.4 ± 8.8 41.5 ± 7.3 c,d
 V45 (%) 7.9 ± 3.7 9.3 ± 3.7 16.8 ± 4.3 17.5 ± 3.3 c,d
 V50 (%) 0.0 ± 0.1 0.0 ± 0.0 0.3 ± 0.2 0.5 ± 0.5 c,d
 Dmean (Gy) 33.9 ± 2.0 34.3 ± 1.9 36.0 ± 1.9 36.3 ± 1.6 c,d
Liver      
 Dmean (Gy) 5.7 ± 1.5 3.9 ± 1.1 6.0 ± 1.1 6.7 ± 1.5 a,c
 MU 1170.8 ± 97.3 1051.5 ± 70.1 1036.1 ± 103.8 831.6 ± 45.2 a,b,d
 Delivery time (min) 6.1 ± 0.6 6.0 ± 0.9 2.2 ± 0.2 2.2 ± 0.4 c,d
  1. a: T-4arc versus T-8arc, b: H-4arc versus H-8arc, c: T-8arc versus H-4arc, d: T-4arc versus H-4arc
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us